|
JP2007501021A
(ja)
*
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
|
DE102004063494A1
(de)
*
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
SG10201400426XA
(en)
|
2006-01-12 |
2014-07-30 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
US8530629B2
(en)
*
|
2009-01-30 |
2013-09-10 |
Ab Biosciences, Inc. |
Lowered affinity antibodies and uses therefor
|
|
US9290577B2
(en)
|
2009-07-03 |
2016-03-22 |
Avipep Pty Limited |
Immuno-conjugates and methods for producing them
|
|
CA2780153A1
(en)
|
2009-11-09 |
2011-05-12 |
Alexion Pharmaceuticals, Inc. |
Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
|
|
JP2013514788A
(ja)
|
2009-12-23 |
2013-05-02 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法２
|
|
SG182408A1
(en)
|
2010-01-11 |
2012-08-30 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
|
SG186397A1
(en)
|
2010-06-22 |
2013-01-30 |
Univ Colorado Regents |
Antibodies to the c3d fragment of complement component 3
|
|
WO2012009760A1
(en)
|
2010-07-20 |
2012-01-26 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
|
US9624294B2
(en)
|
2011-03-14 |
2017-04-18 |
Cellmid Limited |
Antibody recognizing N-domain of midkine
|
|
JP6038121B2
(ja)
|
2011-04-21 |
2016-12-07 |
ガーバン インスティテュート オブ メディカル リサーチ |
修飾された可変ドメイン分子及びその製造及び使用の方法ｂ
|
|
EP2718326B1
(en)
|
2011-06-13 |
2020-08-19 |
CSL Limited |
Antibodies against g-csfr and uses thereof
|
|
KR101982899B1
(ko)
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
ＴＬ1ａ에 대한 항체 및 그의 용도
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
WO2013188693A1
(en)
|
2012-06-15 |
2013-12-19 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
|
WO2014117220A1
(en)
|
2013-02-01 |
2014-08-07 |
Transbio Ltd |
Anti-cd83 antibodies and use thereof
|
|
CN117843785A
(zh)
|
2013-02-07 |
2024-04-09 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
|
RU2718054C2
(ru)
|
2013-11-28 |
2020-03-30 |
СиЭсЭл ЛИМИТЕД |
Способ лечения нефропатии
|
|
WO2015089585A1
(en)
|
2013-12-18 |
2015-06-25 |
Csl Limited |
Method of treating wounds
|
|
EP3209695A4
(en)
|
2014-10-23 |
2018-05-30 |
DendroCyte BioTech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
AU2015336946A1
(en)
|
2014-10-23 |
2017-04-13 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
ES2717308T3
(es)
|
2014-12-06 |
2019-06-20 |
Gemoab Monoclonals Gmbh |
Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
|
|
KR102654033B1
(ko)
*
|
2014-12-08 |
2024-04-02 |
1글로브 바이오메디칼 씨오., 엘티디. |
가용성 유니버셜 adcc 증강 합성 융합 유전자 및 펩티드 기술 및 그 용도
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
US11254744B2
(en)
|
2015-08-07 |
2022-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
AU2016361462B2
(en)
|
2015-11-27 |
2023-09-21 |
Csl Limited |
CD131 binding proteins and uses thereof
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
US20190248920A1
(en)
|
2016-09-23 |
2019-08-15 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP4512469A3
(en)
|
2017-09-11 |
2025-05-21 |
Monash University |
Binding proteins to the human thrombin receptor, par4
|
|
JP7793287B2
(ja)
|
2017-10-18 |
2026-01-05 |
シーエスエル リミティド |
ヒト血清アルブミン変異体およびその使用
|
|
JP7542438B2
(ja)
*
|
2017-11-21 |
2024-08-30 |
ノバルティス アーゲー |
腫瘍関連抗原に対する三重特異性結合分子及びその使用
|
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
WO2019114768A1
(en)
|
2017-12-12 |
2019-06-20 |
Biocytogen Jiangsu Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
|
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
|
US12281160B2
(en)
|
2018-03-23 |
2025-04-22 |
Csl Limited |
Method of treating asthma
|
|
CA3100071A1
(en)
|
2018-05-16 |
2019-11-21 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
|
AR115730A1
(es)
|
2018-07-10 |
2021-02-17 |
Regeneron Pharma |
Modificación de moléculas de unión para minimizar interacciones pre-existentes
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
CN109776683B
(zh)
*
|
2019-03-19 |
2020-04-07 |
益科思特(北京)医药科技发展有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
CN111909268B
(zh)
*
|
2019-05-07 |
2022-04-19 |
北京天成新脉生物技术有限公司 |
低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
|
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
WO2021119761A1
(en)
|
2019-12-20 |
2021-06-24 |
Hudson Institute of Medical Research |
Cxcl10 binding proteins and uses thereof
|
|
US20230128499A1
(en)
*
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
|
US12583929B2
(en)
|
2020-06-04 |
2026-03-24 |
CSL Innovation Pty Ltd |
Method of treating acute respiratory distress syndrome
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
EP4182475A2
(en)
|
2020-07-17 |
2023-05-24 |
Onena Medicines S.L. |
Antibodies against lefty proteins
|
|
CN114656562B
(zh)
*
|
2020-12-23 |
2023-11-03 |
北京天广实生物技术股份有限公司 |
结合人和猴cd3的抗体及其应用
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
JP2024523033A
(ja)
|
2021-06-17 |
2024-06-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規の三重特異的結合分子
|
|
US20260061078A1
(en)
|
2022-08-31 |
2026-03-05 |
Universität Zürich |
Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
|
|
IL325176A
(en)
|
2023-07-05 |
2026-02-01 |
CSL Innovation Pty Ltd |
Methods for treating or preventing a complication of sickle cell disease
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|